Improvement of the qmosRT-PCR Assay and Its Application for the Detection and Quantitation of the Three Serotypes of the Novel Oral Polio Vaccine in Stool Samples.

OPV clinical samples nOPV poliovirus vaccines virus excretion

Journal

Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355

Informations de publication

Date de publication:
19 Nov 2023
Historique:
received: 06 10 2023
revised: 09 11 2023
accepted: 10 11 2023
medline: 25 11 2023
pubmed: 25 11 2023
entrez: 25 11 2023
Statut: epublish

Résumé

Recently, genetically stable novel OPVs (nOPV) were developed by modifying the genomes of Sabin viruses of conventional OPVs to reduce the risk of reversion to neurovirulence and therefore the risk of generating circulating vaccine-derived polioviruses. There is a need for specific and sensitive methods for the identification and quantification of nOPV viruses individually and in mixtures for clinical trials and potentially for manufacturing quality control and environmental surveillance. In this communication, we evaluated and improved the quantitative multiplex one-step reverse transcriptase polymerase chain reaction (qmosRT-PCR) assay for the identification and quantification of nOPV viruses in samples with different formulations and virus concentrations and in virus-spiked stool samples. The assay was able to specifically identify at least 1 log

Identifiants

pubmed: 38006061
pii: vaccines11111729
doi: 10.3390/vaccines11111729
pmc: PMC10675353
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Bill & Melinda Gates Foundation
ID : OPP1150001
Pays : United States

Références

Nucleic Acids Res. 1984 Oct 25;12(20):7787-92
pubmed: 6093054
Lancet. 2014 Oct 25;384(9953):1505-12
pubmed: 25018120
J Virol Methods. 2018 Sep;259:74-80
pubmed: 29920299
China CDC Wkly. 2020 Mar 14;2(11):176-179
pubmed: 34594619
J Infect Dis. 2018 Jan 17;217(3):371-380
pubmed: 29304199
Nature. 2023 Jul;619(7968):135-142
pubmed: 37316671
Lancet Infect Dis. 2016 Dec;16(12):1377-1384
pubmed: 27638357
J Infect Dis. 2017 Jul 1;216(suppl_1):S176-S182
pubmed: 28838194
J Infect Dis. 2006 May 15;193(10):1344-9
pubmed: 16619180
Lancet. 2021 Jan 2;397(10268):27-38
pubmed: 33308427
J Hyg (Lond). 1966 Mar;64(1):105-20
pubmed: 5219018
J Virol. 2006 Sep;80(17):8653-63
pubmed: 16912313
J Virol. 1990 Oct;64(10):4922-9
pubmed: 2168976
Biologicals. 2020 Sep;67:94-111
pubmed: 32660862
MMWR Morb Mortal Wkly Rep. 2019 Nov 15;68(45):1024-1028
pubmed: 31725706
N Engl J Med. 2018 Aug 30;379(9):834-845
pubmed: 30157398
J Infect Dis. 2017 Jul 1;216(suppl_1):S40-S45
pubmed: 28838167
PLoS Pathog. 2012;8(4):e1002599
pubmed: 22532797
J Med Virol. 1990 Oct;32(2):92-5
pubmed: 2177777
NPJ Vaccines. 2020 Mar 20;5(1):26
pubmed: 32218998
J Clin Microbiol. 2009 Jun;47(6):1939-41
pubmed: 19386844
Virology. 1992 Aug;189(2):415-22
pubmed: 1641974
Virology. 1993 Jan;192(1):18-26
pubmed: 8390752

Auteurs

Hasmik Manukyan (H)

Division of Viral Products, Center for Biologics Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA.

Erman Tritama (E)

Research and Development Division, PT. BioFarma, Bandung 40161, Indonesia.

Rahnuma Wahid (R)

Center for Vaccine Innovation and Access, PATH, Seattle, WA 98121, USA.

Jennifer Anstadt (J)

Center for Vaccine Innovation and Access, PATH, Seattle, WA 98121, USA.

John Konz (J)

Center for Vaccine Innovation and Access, PATH, Seattle, WA 98121, USA.

Konstantin Chumakov (K)

Division of Viral Products, Center for Biologics Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA.

Majid Laassri (M)

Division of Viral Products, Center for Biologics Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA.

Classifications MeSH